Literature DB >> 29892655

Data on specificity of [18F]GE180 uptake for TSPO expression in rodent brain and myocardium.

Maximilian Deussing1, Tanja Blume1,2, Lena Vomacka1, Christoph Mahler3,4, Carola Focke1, Andrei Todica1, Marcus Unterrainer1, Nathalie L Albert1, Simon Lindner1, Barbara von Ungern-Sternberg1, Karlheinz Baumann5, Andreas Zwergal6, Peter Bartenstein1,7, Jochen Herms2,7,8, Axel Rominger1,7, Matthias Brendel1.   

Abstract

Data in this article show radioligand uptake (to gamma counter and positron-emission-tomography) as well as polymerase chain reaction analyses of 18 kDa translocator protein (TSPO) quantification. We confirmed specificity of [18F]GE180 binding of rodent brain and myocardium by blocking experiments with prior application of non-radioactive GE180, using dynamic in vivo positron-emission-tomography and ex vivo gamma counter measurements. Expression of TSPO was compared between rodent brain and myocardium by quantitative polymerase chain reaction.

Entities:  

Year:  2018        PMID: 29892655      PMCID: PMC5992977          DOI: 10.1016/j.dib.2018.04.133

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data Blocking by pretreatment with non-radioactive GE180 for quantification of specific [18F]GE180 TSPO binding in rodent brain and myocardium to positron-emission-tomography. Regional analysis for characterization of [18F]GE180 binding specificity in different areas of the rodent brain. Data provide information about the physiological relationship between specific 18 kDa translocator protein (TSPO) tracer signal in normal rodent brain and myocardium. Quantitative polymerase chain reaction gives additional information about the relative magnitudes of TSPO expression in brain and myocardium.

Data

We observed that the myocardium presents a potential extra-cerebral reference region for [18F]GE180 TSPO positron-emission-tomography quantitation [1]. The following data provide additional information about the association and specificity of brain and myocardium TSPO tracer binding, as obtained by blocking experiments (Fig. 1, Fig. 2). Furthermore, we performed quantitative polymerase chain reaction for assessment of TSPO gene expression in brain and myocardium, independent of tracer-based measurements (Fig. 3).
Fig. 1

Gamma counter measurements of tracer uptake in brain and myocardium ex vivo. (A) Bar graphs (logarithmic scale) show %-injected dose-(ID)/g at 107 min after injection of [18F]GE180 with (red) and without (blue) prior blocking with excess non-radioactive GE180 (1000:1). Specific binding was estimated to be 36% in the brain and 80% in the myocardium. Absolute specific binding was 17-fold higher in the myocardium when compared to the brain. (B) Correlation between %-ID/g of brain and myocardium in single mice indicate a relationship between specific TSPO tracer binding in the two tissues, whereas nonspecific binding did not correlate (R2 < 0.2). Data derive from N = 5 unblocked and N = 7 blocked C57Bl/6 mice at seven months of age. Error bars indicate standard deviations. Single data points are available in the supplement.

Fig. 2

Dynamic and regional in vivo positron-emission-tomography (PET) measurements of the brain. (A) Mean dynamic brain PET standardized uptake value (SUV) plots for groups of unblocked (blue) and blocked (red) mice during 90 min after injection of [18F]GE180. Error bars indicate standard deviations. (B) Regional analysis shows axial slices of 60–90 min [18F]GE180 PET SUV projected upon a magnetic resonance imaging template [2]. Upper row illustrates mice with prior blocking by a large mass dose of GE180 (1000:1), whereas the middle row shows unblocked mice. Voxel-wise percentage of specific binding in the rodent brain is depicted in the bottom row. Highest specific binding was observed in regions with high abundance of ependymal glia cells, e.g. adjacent to the fourth ventricle, whereas specific binding in the cortex was low. Data derive from N = 3 unblocked and N = 5 blocked C57Bl/6 mice at seven months of age. Error bars indicate standard deviations. Single data points are available in the supplement.

Fig. 3

Quantitative polymerase chain reaction assessment of TSPO gene expression in brain and myocardium. Bar graphs show relative normalized (actin-beta and glyceraldehyde 3-phosphate dehydrogenase) TSPO expression as assessed by the quantitative polymerase chain reaction. TSPO expression was 11-fold higher in the myocardium compared to that in brain. Data derive from N = 6 C57Bl/6 mice at seven months of age. Error bars indicate standard deviations. Single data points are available in the supplement.

Gamma counter measurements of tracer uptake in brain and myocardium ex vivo. (A) Bar graphs (logarithmic scale) show %-injected dose-(ID)/g at 107 min after injection of [18F]GE180 with (red) and without (blue) prior blocking with excess non-radioactive GE180 (1000:1). Specific binding was estimated to be 36% in the brain and 80% in the myocardium. Absolute specific binding was 17-fold higher in the myocardium when compared to the brain. (B) Correlation between %-ID/g of brain and myocardium in single mice indicate a relationship between specific TSPO tracer binding in the two tissues, whereas nonspecific binding did not correlate (R2 < 0.2). Data derive from N = 5 unblocked and N = 7 blocked C57Bl/6 mice at seven months of age. Error bars indicate standard deviations. Single data points are available in the supplement. Dynamic and regional in vivo positron-emission-tomography (PET) measurements of the brain. (A) Mean dynamic brain PET standardized uptake value (SUV) plots for groups of unblocked (blue) and blocked (red) mice during 90 min after injection of [18F]GE180. Error bars indicate standard deviations. (B) Regional analysis shows axial slices of 60–90 min [18F]GE180 PET SUV projected upon a magnetic resonance imaging template [2]. Upper row illustrates mice with prior blocking by a large mass dose of GE180 (1000:1), whereas the middle row shows unblocked mice. Voxel-wise percentage of specific binding in the rodent brain is depicted in the bottom row. Highest specific binding was observed in regions with high abundance of ependymal glia cells, e.g. adjacent to the fourth ventricle, whereas specific binding in the cortex was low. Data derive from N = 3 unblocked and N = 5 blocked C57Bl/6 mice at seven months of age. Error bars indicate standard deviations. Single data points are available in the supplement. Quantitative polymerase chain reaction assessment of TSPO gene expression in brain and myocardium. Bar graphs show relative normalized (actin-beta and glyceraldehyde 3-phosphate dehydrogenase) TSPO expression as assessed by the quantitative polymerase chain reaction. TSPO expression was 11-fold higher in the myocardium compared to that in brain. Data derive from N = 6 C57Bl/6 mice at seven months of age. Error bars indicate standard deviations. Single data points are available in the supplement.

Experimental design, materials and methods

Radiochemistry

Radiosynthesis of [18F]GE180 was performed as previously described [3], with slight modifications [4], in a procedure yielding radiochemical purity > 98%, and specific activity of 1400 ± 500 GBq/µmol at end of synthesis. For blocking, non-radioactive GE180 was used at a mass concentration ratio of 1000:1 compared to the radiolabeled ligand.

Gamma counter analysis

We performed blocking experiments with excess non-radioactive tracer for quantification of specific [18F]GE180 binding components in the rodent brain and myocardium. A total of twelve female C57Bl6 mice were analyzed at the age of seven months. Isoflurane anesthesia (1.5% in 2–4 l/min O2) was maintained during the experimental procedure, and mice were finally killed by cervical decapitation at 107 min post injection, while in a state of deep narcosis. Five mice received an injection of 14.7 ± 2.2 MBq [18F]GE180 into the tail vein (150 µl saline) Seven mice received an injection of excess non-radioactive GE180 (1000:1) prior to injection of 14.5 ± 2.1 MBq [18F]GE180 (in 150 µl saline) to a tail vein. Brain and myocardium tissues were quickly removed, and radioactivity concentration was measured in a gamma counter (Cobra Quantum 5002, Packard) with decay-correction to time of tracer injection [5].

Positron-emission-tomography acquisition and analysis

A subset of mice (N = 5 with blocking and N = 3 without blocking) was placed in the tomograph (Siemens Inveon DPET) immediately after injection of [18F]GE180, whereupon we began a 90 min dynamic emission recording as described previously [6]. A 15 min transmission scan was then obtained using a rotating [57Co] point source. The image reconstruction procedure consisted of three-dimensional ordered subset expectation maximization with four iterations and twelve subsets followed by a maximum a posteriori algorithm with 32 iterations. Framing was 3 × 60 s, 6 × 180 s, 9 × 300 s, 3 × 600 s. Scatter and attenuation correction were performed and a decay correction for [18F] was applied. With a zoom factor of 1.0 and a 128 × 128 × 159 matrix, a final voxel dimension of 0.78 × 0.78 × 0.80 mm was obtained. Summations of the dynamic emission datasets were manually co-registered to a magnetic resonance imaging mouse atlas [2] by a rigid-body transformation using the PMOD fusion tool (V3.5, PMOD Technologies Ltd.), after blinding the reader to the mouse status (blocked/unblocked). In the second step, a reader-independent automatic re-registration to tracer-specific templates was performed, as reported previously [7]. Initial manual positron-emission-tomography to magnetic resonance imaging atlas fusion images were normalized by non-linear brain normalization to the template using the PMOD brain normalization tool (equal modality; smoothing by 0.6 mm; nonlinear warping; 16 iterations; frequency cutoff 3; regularization 1.0; no thresholding). The concatenation of both transformations was then applied to positron-emission-tomography frames in the native space, to obtain optimal resampling with a minimum of interpolation. The whole brain [18F]GE180 concentration (standardized uptake value; SUV) was measured in a volume-of-interest defined by the magnetic resonance imaging template. The volume-of-interest, comprising 525 mm3, included the entire cerebrum, cerebellum, brainstem and olfactory bulb. The 60–90 min image frames were used to calculate voxel-wise percentages of specific [18F]GE180 binding throughout the rodent brain.

Quantitative TSPO polymerase chain reaction

RNA isolation and reverse transcription

Brain and heart tissue from adult mice was immediately frozen to − 80 °C in liquid nitrogen after resection. Tissue was lysed with QIAzol Lysis Reagent (Quiagen) and homogenized. The InviTrap® Spin Universal RNA Mini Kit (Stratec) was used to isolate RNA and to separate it from contaminating DNA. RNA concentration was measured with NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Extracted RNA was assessed based on spectral data and purity ratios (A260/A280). Reverse transcription from 50 µL of 50 ng/µL RNA was performed by incubating with 4 µL 25x dNTPs, 10 µL 10x random primers, 5 µL MultiScribe™ Reverse Transcriptase 50 U/µL, 21 µL Nuclease-free H2O for 10 min at 25 °C, then 120 min at 37 °C. The transcription was terminated by incubating at 85 °C for 5 min.

Real-time polymerase chain reaction

TSPO mRNA expression was measured using a CFX connect optics module RT-System (BioRad, Hercules, CA, USA). cDNA template 9 µl was added to 20× TaqMan® Gene Expression Assay Mm00437828_m1 1 µl and 2x TaqMan® Gene Expression Master Mix 10 µl. Thermal cycling conditions were 2 min at 50 °C and 10 min at 95 °C, followed by 40 cycles at 98 °C for 15 s and at 60 °C for 1 min. To test specificity of the polymerase chain reaction product a melt curve analysis was performed. TSPO expression was normalized to the housekeeping genes Actin-beta and glyceraldehyde 3-phosphate dehydrogenase expression was used for comparative quantification.
Subject areaNuclear Medicine
More specific subject areaPreclinical PET imaging of neuroinflammation
Type of dataPET images, blocking plots, correlation plots
How data was acquired[18F]GE180 TSPO PET, gamma counter, TSPO qPCR
Data formatQuantification of PET and tissue samples, Listmode, NIFTI
Experimental factorsC57Bl6 mice, cold GE180, [18F]GE180, Analysis of TSPO expression
Experimental featuresTSPO PET, TSPO qPCR
Data source locationDepartment of Nuclear Medicine, Munich, Germany
Data accessibilityThe data is provided within this article
  6 in total

1.  Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study.

Authors:  A Dorr; J G Sled; N Kabani
Journal:  Neuroimage       Date:  2007-01-23       Impact factor: 6.556

2.  Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study.

Authors:  Matthias Brendel; Federico Probst; Anna Jaworska; Felix Overhoff; Viktoria Korzhova; Nathalie L Albert; Roswitha Beck; Simon Lindner; Franz-Josef Gildehaus; Karlheinz Baumann; Peter Bartenstein; Gernot Kleinberger; Christian Haass; Jochen Herms; Axel Rominger
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

3.  The development of an automated and GMP compliant FASTlab™ Synthesis of [(18) F]GE-180; a radiotracer for imaging translocator protein (TSPO).

Authors:  Torild Wickstrøm; Alan Clarke; Ingvil Gausemel; Eric Horn; Karina Jørgensen; Imtiaz Khan; Dimitrios Mantzilas; Thanushan Rajanayagam; Dirk-Jan in 't Veld; William Trigg
Journal:  J Labelled Comp Radiopharm       Date:  2013-09-23       Impact factor: 1.921

4.  Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.

Authors:  Matthias Brendel; Andreas Delker; Christina Rötzer; Guido Böning; Janette Carlsen; Clemens Cyran; Erik Mille; Franz Josef Gildehaus; Paul Cumming; Karlheinz Baumann; Harald Steiner; Christian Haass; Jochen Herms; Peter Bartenstein; Axel Rominger
Journal:  Neuroimage       Date:  2013-09-20       Impact factor: 6.556

5.  Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [18F]GE180 PET quantification.

Authors:  Maximilian Deussing; Tanja Blume; Lena Vomacka; Christoph Mahler; Carola Focke; Andrei Todica; Marcus Unterrainer; Nathalie L Albert; Simon Lindner; Barbara von Ungern-Sternberg; Karlheinz Baumann; Andreas Zwergal; Peter Bartenstein; Jochen Herms; Axel Rominger; Matthias Brendel
Journal:  Neuroimage       Date:  2017-10-05       Impact factor: 6.556

6.  Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice.

Authors:  Felix Overhoff; Matthias Brendel; Anna Jaworska; Viktoria Korzhova; Andreas Delker; Federico Probst; Carola Focke; Franz-Josef Gildehaus; Janette Carlsen; Karlheinz Baumann; Christian Haass; Peter Bartenstein; Jochen Herms; Axel Rominger
Journal:  Front Neurosci       Date:  2016-02-29       Impact factor: 4.677

  6 in total
  3 in total

1.  Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study.

Authors:  Marcus Unterrainer; D F Fleischmann; C Diekmann; L Vomacka; S Lindner; F Vettermann; M Brendel; V Wenter; B Ertl-Wagner; J Herms; C Wetzel; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; Nathalie L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-22       Impact factor: 9.236

2.  Reliable quantification of 18F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio.

Authors:  Ralph Buchert; Meike Dirks; Christian Schütze; Florian Wilke; Martin Mamach; Ann-Katrin Wirries; Henning Pflugrad; Linda Hamann; Laura B N Langer; Christian Wetzel; Mario Lukacevic; Andras Polyak; Mariella Kessler; Carlotta Petrusch; Frank M Bengel; Lilli Geworski; Rainer Rupprecht; Karin Weissenborn; Tobias L Ross; Georg Berding
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-23       Impact factor: 9.236

3.  Impact of Partial Volume Correction on [18F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome.

Authors:  Sebastian Schuster; Leonie Beyer; Carla Palleis; Stefanie Harris; Julia Schmitt; Endy Weidinger; Catharina Prix; Kai Bötzel; Adrian Danek; Boris-Stephan Rauchmann; Sophia Stöcklein; Simon Lindner; Marcus Unterrainer; Nathalie L Albert; Lena M Mittlmeier; Christian Wetzel; Rainer Rupprecht; Axel Rominger; Peter Bartenstein; Robert Perneczky; Johannes Levin; Günter U Höglinger; Matthias Brendel; Franziska J Dekorsy
Journal:  Brain Sci       Date:  2022-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.